Paediatric diabetes — which children can gain insulin independence?

Shubha Srinivasan and Kim C Donaghue
Med J Aust 2007; 186 (9): . || doi: 10.5694/j.1326-5377.2007.tb00991.x
Published online: 7 May 2007

Molecular genetics can facilitate a successful switch to oral diabetes therapy

The increase in type 1 and type 2 diabetes in childhood has been well documented worldwide and in Australia.1,2 In addition, the separate entity of monogenic diabetes is increasingly recognised in paediatric diabetes, and now encompasses neonatal diabetes mellitus and maturity onset diabetes of the young (MODY)3 (Box 1). Monogenic diabetes is defined as diabetes caused by a single gene defect. A diagnosis of monogenic diabetes should be considered in a child who is diabetes-associated-autoantibody negative, is diagnosed with diabetes in the first 6 months of life, has a parent with diabetes, and/or is not markedly obese. Although uncommon — its frequency is estimated to be 1%–3% of all childhood diabetes3 — the clinical relevance of this condition is that at least some of those affected (in particular, those with MODY1 and MODY3) can achieve very good diabetes control with sulfonylurea rather than insulin therapy.

  • Shubha Srinivasan1
  • Kim C Donaghue1,2

  • 1 Institute of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Sydney, NSW.
  • 2 University of Sydney, Sydney, NSW.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.